2015-2019 Global Occult Blood Testing Market: US, Europe, Japan - Emerging Opportunities and Business Strategies - Competitive Landscape, Supplier Shares, Country Volume and Sales Segment Forecasts
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease.
During the next ten years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.
This report presents a detailed analysis of the Occult Blood testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5- and 10-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers.
The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.
Contains 243 pages and 8 tables
During the next ten years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.
This report presents a detailed analysis of the Occult Blood testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5- and 10-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers.
The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.
Contains 243 pages and 8 tables
I. INTRODUCTION
II. OCCULT BLOOD WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW
A. Occult Blood: Clinical Significance and Laboratory Practices
B. Instrumentation Review And Market Needs
1. Abbott AxSYM
2. Abbott Architect c 4000
3. Abbott Architect i 2000 Series
4. Abbott Architect ci 8200 System
5. Beckman Coulter UniCel Series
6. Beckman Coulter Access
7. Binding Site ESP 600
8. bioMerieux Mini Vidas
9. Carolina Chemistries BioLis 24i
10. DiaSorin Liaison
11. Horiba ABX Pentra 400
12. Inverness DS
13. J&J Vitros ECi/ECiQ
14. J&J Vitros 3600
15. J&J Vitros 5600
16. Olympus AU 5400
17. Olympus AU 3000i
18. Olympus AU 2700
19. Roche Modular Analytics
20. Roche Cobas Integra 400
21. Roche Cobas Integra 400 Plus
22. Roche Elecsys
23. Roche Cobas c311
24. Siemens ADVIA Centaur
25. Siemens Dimension
26. Siemens Dimension RxL Max
27. Siemens Dimension Vista 500
28. Siemens Immulite
29. Siemens Stratus
30. Tosoh AIA - Series
31. Vital Diagnostics ATAC 8000
32. Vital Diagnostics Envoy 500
C. Current and Emerging Technologies
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
a. Technological Principle
b. Radioimmunoassay (RIA)
c. Enzyme Immunoassays (EIA)
Overview
ELISA
Immunofiltration
Particle - Membrane Capture Immunoassay
Enzyme Amplification
d. Fluorescent Immunoassays
e. Luminescence
Chemiluminescence
Bioluminescence
f. Latex Agglutination
g. Immunoprecipitation
H. Affinity Chromatographu
e. Liposome Flow - Injection Immunoassay
3. Molecular Diagnostics
a. Technology Overview
b. Amplification Methods
PCR
DAP - PCR
Immuno - PCR
QC - PCR
CAR
DNA
HPA
LCR
NASBA
QBR
SDA
3 SR, and others
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis ( 2 - DGE)
8. Biosensors
9. Competing/Complementing Technologies
a. CT
b. MRI
c. NMR
d. PET
e. Photonics Spectroscopy
E. Personal Testing
III. FRANCE: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT
IV. GERMANY: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT
V. ITALY: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT
VI. JAPAN: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT
VII. SPAIN: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT
VIII. U.K.: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT
IX. U.S.A.: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT
X. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
XI. ALTERNATIVE MARKET PENETRATION STRATEGIES
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
1. Marketing Approaches
2. Product Complexity
3. Customer Preference
4. Established Suppliers
5. Emerging Suppliers
6. Major Types of Distributors
7. Market Segmentation Factor
XII. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
XIII. COMPETITIVE PROFILES
Abbott
AdnaGen
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher
Becton Dickinson
Biomedical Diagnostics
bioMerieux
Bio - Rad
Cepheid
Correlogic Systems
Decode Genetics
Diadexus
Diagnocure
Diasorin
Eiken Chemical
Elitech Group
Enterix
Enzo Biochem
Epigenomics
Exact Sciences
Fujirebio
Hologic/Gen - Probe
Guided Therapeutics
Kreatech
Kyowa Medex
Mackay Life Sciences
Myriad Genetics
OncoLab
Ortho - Clinical Diagnostics
Panacea Pharmaceuticals
Polartechnics
Polymedco
PreMD
Qiagen
Quest Diagnostics
Radient Pharmaceuticals
Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Thermo Fisher
Tosoh
Veridex
Wako Pure Chemicals
Wallac/PE
Zila
II. OCCULT BLOOD WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW
A. Occult Blood: Clinical Significance and Laboratory Practices
B. Instrumentation Review And Market Needs
1. Abbott AxSYM
2. Abbott Architect c 4000
3. Abbott Architect i 2000 Series
4. Abbott Architect ci 8200 System
5. Beckman Coulter UniCel Series
6. Beckman Coulter Access
7. Binding Site ESP 600
8. bioMerieux Mini Vidas
9. Carolina Chemistries BioLis 24i
10. DiaSorin Liaison
11. Horiba ABX Pentra 400
12. Inverness DS
13. J&J Vitros ECi/ECiQ
14. J&J Vitros 3600
15. J&J Vitros 5600
16. Olympus AU 5400
17. Olympus AU 3000i
18. Olympus AU 2700
19. Roche Modular Analytics
20. Roche Cobas Integra 400
21. Roche Cobas Integra 400 Plus
22. Roche Elecsys
23. Roche Cobas c311
24. Siemens ADVIA Centaur
25. Siemens Dimension
26. Siemens Dimension RxL Max
27. Siemens Dimension Vista 500
28. Siemens Immulite
29. Siemens Stratus
30. Tosoh AIA - Series
31. Vital Diagnostics ATAC 8000
32. Vital Diagnostics Envoy 500
C. Current and Emerging Technologies
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
a. Technological Principle
b. Radioimmunoassay (RIA)
c. Enzyme Immunoassays (EIA)
Overview
ELISA
Immunofiltration
Particle - Membrane Capture Immunoassay
Enzyme Amplification
d. Fluorescent Immunoassays
e. Luminescence
Chemiluminescence
Bioluminescence
f. Latex Agglutination
g. Immunoprecipitation
H. Affinity Chromatographu
e. Liposome Flow - Injection Immunoassay
3. Molecular Diagnostics
a. Technology Overview
b. Amplification Methods
PCR
DAP - PCR
Immuno - PCR
QC - PCR
CAR
DNA
HPA
LCR
NASBA
QBR
SDA
3 SR, and others
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis ( 2 - DGE)
8. Biosensors
9. Competing/Complementing Technologies
a. CT
b. MRI
c. NMR
d. PET
e. Photonics Spectroscopy
E. Personal Testing
III. FRANCE: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT
IV. GERMANY: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT
V. ITALY: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT
VI. JAPAN: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT
VII. SPAIN: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT
VIII. U.K.: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT
IX. U.S.A.: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT
X. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
XI. ALTERNATIVE MARKET PENETRATION STRATEGIES
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
1. Marketing Approaches
2. Product Complexity
3. Customer Preference
4. Established Suppliers
5. Emerging Suppliers
6. Major Types of Distributors
7. Market Segmentation Factor
XII. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
XIII. COMPETITIVE PROFILES
Abbott
AdnaGen
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher
Becton Dickinson
Biomedical Diagnostics
bioMerieux
Bio - Rad
Cepheid
Correlogic Systems
Decode Genetics
Diadexus
Diagnocure
Diasorin
Eiken Chemical
Elitech Group
Enterix
Enzo Biochem
Epigenomics
Exact Sciences
Fujirebio
Hologic/Gen - Probe
Guided Therapeutics
Kreatech
Kyowa Medex
Mackay Life Sciences
Myriad Genetics
OncoLab
Ortho - Clinical Diagnostics
Panacea Pharmaceuticals
Polartechnics
Polymedco
PreMD
Qiagen
Quest Diagnostics
Radient Pharmaceuticals
Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Thermo Fisher
Tosoh
Veridex
Wako Pure Chemicals
Wallac/PE
Zila
LIST OF TABLES
Major Companies Developing or Marketing Occult Blood Tests
France Occult Blood Test Volume and Diagnostics Sales by Market Segment
Germany Occult Blood Test Volume and Diagnostics Sales by Market Segment
Italy Occult Blood Test Volume and Diagnostics Sales by Market Segment
Japan Occult Blood Test Volume and Diagnostics Sales by Market Segment
Spain Occult Blood Test Volume and Diagnostics Sales by Market Segment
U.K. Occult Blood Test Volume and Diagnostics Sales by Market Segment
U.S.A Occult Blood Test Volume and Diagnostics Sales by Market Segment
Major Companies Developing or Marketing Occult Blood Tests
France Occult Blood Test Volume and Diagnostics Sales by Market Segment
Germany Occult Blood Test Volume and Diagnostics Sales by Market Segment
Italy Occult Blood Test Volume and Diagnostics Sales by Market Segment
Japan Occult Blood Test Volume and Diagnostics Sales by Market Segment
Spain Occult Blood Test Volume and Diagnostics Sales by Market Segment
U.K. Occult Blood Test Volume and Diagnostics Sales by Market Segment
U.S.A Occult Blood Test Volume and Diagnostics Sales by Market Segment